Since the beginning of the pandemic, BioNTech has grown strongly. Now the Mainz-based biotechnology company has advertised numerous additional positions “across all departments”. The focus is on sales.
The Mainz-based corona vaccine manufacturer BioNTech is expanding. An extensive job expansion is planned for the coming months, the company said, according to a report in “Welt am Sonntag.” 500 new positions across all departments are currently being advertised, it said. Before the Corona pandemic, BioNTech employed a good 1,300 people.
The company worked primarily on new therapeutic options against cancer. Together with the US company Pfizer, BioNTech then developed the first vaccine against the corona virus to be approved in many countries last year. For this, the company used the novel mRNA technology, which is also used in the development of cancer immunotherapies. Most recently, BioNTech announced plans to develop a malaria vaccine.
Number of employees grows in pandemicIn the past year and a half, the number of BioNTech employees has already risen to around 2,000. According to the report in “Welt am Sonntag,” the manufacturer now plans to invest in its own sales team of 60 employees for the first time in order to promote the marketing of approved products itself. “We set up BioNTech as a fully integrated company from the very beginning. With our own research and development, production and now also a sales department,” board member Sierk Poetting told the newspaper.
